# Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension

> **NCT00797862** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1254 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Amlodipine
- **DRUG:** hydrochlorothiazide
- **DRUG:** Aliskiren

## Key facts

- **NCT ID:** NCT00797862
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 1254 (ACTUAL)
- **Last updated:** 2011-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00797862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00797862, "Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00797862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*